Vietnam In-Vitro Diagnostics Market was valued at USD 336.07 Million in 2024 and is expected to reach USD 441.23 Million by 2030 with a CAGR of 4.60% during the forecast period.

Vietnam in vitro diagnostics market size reached USD 335.3 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 494.4 Million by 2033, exhibiting a growth rate (CAGR) of 4.19% during 2025-2033. The rising healthcare awareness, rapidly aging population across the region, favorable government initiatives, increasing prevalence of chronic and infectious diseases, significant technological advancements, growing medical tourism, represent some of the key factors driving the market.

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the country level for 2025-2033. Our report has categorized the market based on product & service, technique, application, and end user.

Unlock expert insights on the Vietnam In Vitro Diagnostics (IVD) Market, size at USD 1.5 billion in 2023, featuring key trends and challenges in the sector.

The Vietnam in vitro diagnostics market was valued at USD 1.10 Billion in 2024, driven by increasing government healthcare investments and technological advancements across the region. The market is anticipated to grow at a CAGR of 5.50% during the forecast period of 2025-2034, with the values likely to reach USD 1.88 Billion by 2034. The increased chronic disease prevalence and government healthcare investments, and urbanization are likely to drive the demand for diagnostic solutions in Vietnam during the forecast period.

Gain insights into the Vietnam In-Vitro Diagnostics (IVD) Market size at USD 226 million in 2023, showcasing industry growth driven by technology advancements and regulatory initiatives.

Vietnam In Vitro Diagnostics (IVD) Market is poised for significant growth driven by advancements in diagnostic technology.

The global veterinary diagnostics market is experiencing robust growth, driven by factors such as the increasing pet ownership worldwide, rising prevalence of zoonotic diseases, and advancements in diagnostic technologies. The market is segmented by product type (instruments, reagents & consumables), technique (hematology, immunodiagnostics, molecular diagnostics, etc.), animal type (livestock, companion), and end-user (veterinary hospitals, reference labs). The increasing demand for accurate and rapid diagnostic tests, particularly in companion animal care, is fueling market expansion. Furthermore, the rising adoption of point-of-care testing (POCT) devices is streamlining diagnostic workflows and improving veterinary healthcare access, particularly in remote areas. Technological innovations like advanced molecular diagnostics and automated systems contribute significantly to market growth, enhancing diagnostic accuracy and efficiency. Leading companies like IDEXX Laboratories, Zoetis, and Heska are investing heavily in R&D and strategic acquisitions to consolidate their market positions. The North American region currently dominates the market due to high veterinary healthcare expenditure and advanced infrastructure. However, the Asia-Pacific region exhibits significant growth potential, fueled by increasing pet ownership, rising disposable incomes, and improving veterinary infrastructure. While regulatory hurdles and high costs associated with advanced diagnostic technologies can present challenges, the overall market outlook remains positive. The forecast period (2025-2033) anticipates a sustained CAGR driven by the factors mentioned above, with a significant increase in market size. Competitive landscape analysis suggests a trend toward consolidation, with mergers and acquisitions playing a crucial role in shaping the industry's future. The market is poised for substantial growth, with potential for innovative diagnostic solutions to further transform veterinary healthcare. Recent developments include: January 2024: Center Point Bio-Tech, LLC (CPB) launched AlphaION at the 2024 Veterinary Meeting & Expo in the U.S. AlphaION is a novel, patent-pending veterinary practice diagnostic system., November 2023: Antech opened a new U.K. veterinary diagnostics laboratory in Warwick. The move would expand the company’s U.K. lab network., March 2023: QIAGEN N.V. partnered with Servier to develop a companion diagnostic test for TIBSOVO, an isocitrate dehydrogenase-1 (IDH1) inhibitor. The solution was launched for treating blood cancer Acute Myeloid Leukemia (AML). Under this collaboration, QIAGEN would develop and validate a real-time in vitro PCR test that can be used to detect IDH1 gene mutations in AML patients in whole blood and bone marrow aspirates., February 2023: Heska Corporation announced the availability of VolitionRx Limited’s Nu. Q Vet Cancer Test for pre-order through its point-of-care segment., February 2023: Virbac opened its research and development center dedicated to warm water aquaculture in Vietnam. It also serves as a diagnostic center., October 2022: Avante Animal Health and Vetiqure AB, a subsidiary of ChemoTech, signed a letter of intent to get into a distribution agreement and install approximately six vetIQure systems at various university hospitals and leading clinics., January 2022: IDEXX Laboratories, Inc. extended the reference laboratory menu by including innovative genomic diagnostics. The initiative helped expand the company's oncology offerings.. Key drivers for this market are: Increasing Outbreaks of Veterinary Diseases and Positive Government Support to Boost Adoption. Potential restraints include: Shortage of Skilled Veterinary Healthcare Providers to Hinder Industry Growth. Notable trends are: Growing Adoption of Point-of-Care in Animal Diagnostics due to its Potential Advantages.